3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
2
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Lymphatic Metastasis
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Carcinosarcoma
1
Carcinoma, Squamous Cell
1
Anus Neoplasms
1
Interventions
Cisplatin
8
Radiotherapy
5
Paclitaxel
5
Docetaxel
5
Cetuximab
4
Carboplatin
4
pembrolizumab
3
figitumumab
2
cemiplimab
2
advexin
2
Radiation
2
Methotrexate
2
Fluorouracil
2
Drug Therapy
2
Bleomycin
2
vandetanib
1
talimogene laherparepvec
1
sintilimab
1
nedaplatin
1
nanocis
1
methyl 5-aminolevulinate
1
ficlatuzumab
1
dusquetide
1
brigatinib
1
avasopasem manganese
1
alpha-2'-deoxythioguanosine
1
Vinorelbine
1
Tretinoin
1
Tirapazamine
1
Technetium-99
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Carcinoma, Squamous Cell
×
Indocyanine Green
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled